Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA host gene 4 (SNHG4) is a long non-coding RNA (lncRNA) that acts as a host gene for small nucleolar RNAs, with its introns typically processed into snoRNAs and its exons recombined to participate in cytoplasmic or nuclear regulatory functions[2]. SNHG4 is predominantly located in the nucleus and is implicated in the regulation of RNA splicing, RNA processing, ribosome biogenesis, and cell cycle control[1][2]. It is frequently upregulated in multiple cancers, notably hepatocellular carcinoma and endometrial cancer, where its expression correlates with tumor progression, increased cell proliferation, invasion, poor prognosis, and lower overall survival rates[1][2]. Mechanistically, SNHG4 influences cellular signaling pathways such as MAPK/ERK, mTOR, and EMT-related signaling, often acting via interactions with microRNAs (e.g., miR-154, miR-206) and transcription factors such as SP-1[1][2]. SNHG4 is being investigated as a prognostic biomarker and a potential therapeutic target in oncology, though direct pharmacologic modulators or drugs targeting SNHG4 have not yet been established in clinical practice[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA host gene 4 (SNHG4).